Data gathered: October 5
Alternative Data for Bolt Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 81 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 754 | Sign up | Sign up | Sign up |
| Twitter Mentions | 31 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the discovery, development and commercialization of pharmaceutical products. The company is headquartered in Redwood city, California.
| Price | $0.65 |
| Target Price | Sign up |
| Volume | 167,800 |
| Market Cap | $24M |
| Year Range | $0.58 - $1.5 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest UpdateSeptember 28 - ETF Daily News |
|
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decrease in Short InterestSeptember 19 - ETF Daily News |
Bolt Metals Acquires Promising Mining PropertyOctober 2 - TipRanks |
|
HER2 Positive Breast Cancer Treatment Pipeline Landscape 2024: Insight Report Reveals Over 60 Companies Developing Innovative TherapiesSeptember 25 - GlobeNewswire |
|
Groundbreaking Market Report Forecasts Significant Growth in Cancer Immunotherapy by 2027September 19 - GlobeNewswire |
|
Bolt Metals Expands Mining Property Amid Supply ConcernsSeptember 15 - TipRanks |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 1.3M | 8.4M | -7.2M | -21M | -19M | -0.460 |
| Q1 '24 | 5.3M | 5.8M | -560,000 | -11M | -17M | -0.280 |
| Q4 '23 | 2.1M | 5.5M | -3.4M | -18M | -19M | -0.470 |
| Q3 '23 | 2.5M | 5.8M | -3.2M | -16M | -18M | -0.430 |
| Q2 '23 | 1.4M | 5.6M | -4.2M | -18M | -19M | -0.480 |
Insider Transactions View All
| Quinn William P. filed to buy 36,272 shares at $1. December 13 '23 |
| Quinn William P. filed to buy 28,772 shares at $0.8. December 13 '23 |
| Schatzman Randall C filed to buy 12,859 shares at $0.8. February 6 '24 |
| Perez Edith A. filed to buy 46,612 shares at $0.8. February 6 '24 |
| Yonehiro Grant filed to buy 8,918 shares at $0.8. February 6 '24 |
Similar companies
Read more about Bolt Biotherapeutics (BOLT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Bolt Biotherapeutics?
The Market Cap of Bolt Biotherapeutics is $24M.
What is the current stock price of Bolt Biotherapeutics?
Currently, the price of one share of Bolt Biotherapeutics stock is $0.65.
How can I analyze the BOLT stock price chart for investment decisions?
The BOLT stock price chart above provides a comprehensive visual representation of Bolt Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bolt Biotherapeutics shares. Our platform offers an up-to-date BOLT stock price chart, along with technical data analysis and alternative data insights.
Does BOLT offer dividends to its shareholders?
As of our latest update, Bolt Biotherapeutics (BOLT) does not offer dividends to its shareholders. Investors interested in Bolt Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Bolt Biotherapeutics?
Some of the similar stocks of Bolt Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.